Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin's significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients. Through Novamind's clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. "Due to psychedelic medicine's generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies." Paul Thielking, Chief Scientific Officer (CSO) of Novamind. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work," explained Dr.
"Patients receiving palliative care have higher rates of depression than the general population. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to launch Psychedelic Palliative Care by Novamind (the "Palliative Program") at its recently opened clinic and research site in Murray, Utah.Īmong the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness. TORONTO, ON / ACCESSWIRE / Octo/ Novamind Inc. Novamind logo by N/A is licensed under Novamind Inc Specialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illness
0 kommentar(er)
